# Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

> **NCT07339488** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chuangzhen Chen** · enrollment: 43 (estimated)

## Conditions studied

- Borderline Resectable Carcinoma
- Unresectable Cancer
- Esophageal Squamous Cell Carcinoma (ESCC)
- Immune Checkpoint Inhibitor
- Chemotherapy
- Radiotherapy
- Tislelizumab

## Interventions

- **RADIATION:** Intestinal Low Dose Radiotherapy-1Gy
- **DRUG:** PD-1/PD-L1 inhibitors
- **DRUG:** Chemotherapy
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT07339488
- **Lead sponsor:** Chuangzhen Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2028-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- BeOne Medicines

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07339488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07339488, "Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT07339488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*